BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Press Releases

Novo Nordisk Sinks US $136M into Landmark Stem Cell Manufacturing Facility in Denmark

By Leave a Comment

The Novo Nordisk Foundation will invest up to US$136 million in a new cell therapy manufacturing facility in Lyngby, Denmark.

The Novo Nordisk Foundation is making a substantial commitment of up to DKK 950 million (US $136M) to create an advanced facility dedicated to scaling up cell therapies for use in human patients. This facility, known as the Novo Nordisk Foundation Cellerator, is poised to address a critical gap in the Danish cell therapy ecosystem. Its overarching goal is to facilitate the transition from groundbreaking cell therapy research to tangible treatments for individuals grappling with various chronic diseases such as chronic heart failure, Parkinson’s disease, kidney disease, type 1 diabetes, and several forms of cancer. [Read more…]

dG Medical Group Launches Regenerative Medicine Program using Mesenchymal Stem Cell Exosomes

By 1 Comment

Clearwater, FL, September 13, 2023 –  dG Medical Group, with a dedication to providing patients, physicians, and clinicians the most advanced and beneficial technology, is launching research studies in the use of Mesenchymal Stem Cell (MSC) Exosomes for a variety of medical conditions. This landmark of an achievement makes it the only product legally permitted to be sold for clinical use through research. [Read more…]

Shoreline Biosciences Smashes Fate Therapeutics and Whitehead Institute in Legal Battle Over iPSCs

By Leave a Comment

Shoreline Biosciences Wins a Comprehensive Summary Judgment Victory on All Claims Brought by Fate Therapeutics and Whitehead Institute on iPSC Generation and Use

September 7, 2023, SAN DIEGO – Shoreline Biosciences, Inc., a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNKs) and macrophages (iMACs), today announced a major milestone in its patent litigation with Fate Therapeutics, Inc. and the Whitehead Institute in the U.S. District Court for the Southern District of California. [Read more…]

Danaher’s Ventures Pours $18M into BlueWhale Bio, a Cell Therapy Manufacturing Company Co-founded by Carl June

By Leave a Comment

  • BlueWhale Bio Science Team led by world-renowned immunotherapy pioneers Carl June and James Riley of University of Pennsylvania
  • BlueWhale Bio technology platform aims to bring cell and gene therapy benefits to patients faster and at lower cost
  • Investors include Danaher Ventures, Novalis LifeSciences, Marshall Wace, Hillhouse Capital

[Read more…]

PeptiGrowth Inc. is Launching a Novel Synthetic Peptide VEGF-alternative peptide (VEGFR2 agonist)

By Leave a Comment

PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “VEGF alternative peptide (VEGFR2 agonist)” which has equivalent function to recombinant VEGF (Vascular Endothelial Growth Factor). This product will be on the market at the end of September 2023. [Read more…]

BioInformant's World-Class Clients

Shopping cart0
There are no products in the cart!
Continue shopping
0